肿瘤抑制素及其受体在原发性肝细胞癌临床各期的表达研究

Research on Expression of Oncostatin M and its Receptor at Clinical Stages of Hepatocellular Carcinoma

目的探讨原发性肝细胞癌(HCC)临床各期中肿瘤抑制素(OSM)、肿瘤抑制素受体(OSMR)表达及其在HCC的发生发展中的作用机制。方法用固相夹心酶联免疫吸附法(ELISA)检测30例HCC(临床Ⅰ期15例、Ⅱ期10例、Ⅲ期5例),5例正常肝和6例肝血管瘤组织(对照组)中OSM、OSMR的表达水平。结果30例HCC组织中OSM、OSMR表达水平明显低于对照组(P<0.05);HCC组织中临床Ⅲ期OSM表达低于Ⅰ、Ⅱ期(P<0.05);OSMR临床Ⅰ、Ⅱ、Ⅲ期无显著差异(P>0.05)。在低、中分化组HCC组织中OSM表达明显低于高分化组(P<0.05),低分化与中分化组间差异无统计学意义(P>0.05);HCC组织中OSMR表达3组之间差异均无统计学意义(P>0.05)。结论OSM、OSMR的表达和HCC临床分期及肿瘤的分化程度密切相关。

Objective To explore the expression of oncostatin M （OSM） and its receptor （OSMR） at the clinical stages of hepatoma tissues and possible mechanisms by which they affect hepatocellular carcinoma （HCC）. Methods ELISA immunohistochemistry was used to detect the expression of OSM and OSMR in hepatoma tissues in 30 patients with HCC, 5 normal liver tissues and 6 tissues of hemangiomas. Results The expression of OSM and OSMR in 30 patients with HCC, compared with the control group, was significantly lower than the tissues of liver and hemangiomas （P 〈 0.05）. The expression of OSM at the clinical stage Ⅲ HCC was lower than Ⅰ or Ⅱ （P 〈 0. 05）, but OSMR expression of Ⅰ , Ⅱ , Ⅲ was of no significant differences （P 〉 0.05）. In the low and medium differentiation group OSM expression in HCC tissues was signifi- cantly lower than well-differentiated group （P 〈 0.05） the low differentiated and the Medium differentiation group was no significant difference （P 〉 0.05） ; OSMR expression in HCC tissues among the three groups were no statistically significant difference （P 〉 0.05）. Conclusion The clinical stages of HCC and the degree of differentiation of the tumor are closely related to the OSM, OSMR expression.